SHZUY yields 5.28% · JNJ yields 2.13%● Live data
📍 SHZUY pulled ahead of the other in Year 1
Combined, SHZUY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHZUY + JNJ for your $10,000?
The Shizuoka Bank, Ltd., a regional bank, provides various banking products and services. The company operates through Banking Operations and Leasing Operations segments. The Banking Operations segment consist of the banking business centered on deposits, loans, investment securities, and exchange transactions. The Leasing Operations segment includes lease transactions centered on finance leases. It also provides corporate and financial management advisory, bill collection, leasing, and finance and securities-related services. In addition, the company engages in the guarantee of housing loans, credit cards and prepaid cards, and consumer loans; development and operation of computer systems; provision of public-offering assistance support for corporate rehabilitation, and fee-based job placement and general administration services; and appraisal of real estate for loan collateral, as well as operation of centers for loans, remittance, and bill collection. Further, it is involved in the provision of part-time employee management, finance and securities-related, and monetary receivables purchasing services; and making, printing, and binding of various documents. As of July 1, 2021, the company operated a head office, 178 branches, and 27 sub-branches in Shizuoka Prefecture, Tokyo, Osaka, and Nagoya; 2 branches in New York and Los Angeles; 1 in Europe; and 1 branch in Hong Kong, as well as 2 representative offices in Shanghai and Singapore. The Shizuoka Bank, Ltd. was founded in 1943 and is headquartered in Shizuoka, Japan.
Full SHZUY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.